Analysts Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Price Target at $8.30
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have given a buy recommendation and one […]
22 Sep 05:14 · The Cerbat Gem